

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

This is an Abridged Prospectus containing salient features of the Prospectus dated August 6, 2024 filed with Registrar of companies, Ahmedabad (the "Prospectus"). You are encouraged to read greater details available in the Prospectus on the website of the Stock Exchange, (www.bseindia.com), Company (www.maplehospital.in) and Lead Manager (www.fedsec.in)



(Please scan this QR Code to view the Prospectus)

THIS ABRIDGED PROSPECTUS CONSISTS 8 PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.



BROACH LIFECARE HOSPITAL LIMITED

Corporate Identification Number: U86100GJ2023PLC140499, Date of Incorporation: April 25, 2023

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
501, 5th Floor, Corporate House, above Bharuch Orthopedic Hospital, R K Casta, Bharuch, Gujarat 392001 India	NA	Mrs. Swati Sharma, Company Secretary & Compliance Officer	Email Id: info@maplehospital.in Contact No.: +91 94291 87226	www.maplehospital.in

PROMOTERS OF THE COMPANY: DR. JAYKUMAR NARENDRA VYAS, DR. SHACHI JAYKUMAR VYAS AND MRS. DHYUTI KRUPESH JOSH

DETAILS OF ISSUE TO PUBLIC

Type of Issue (Fresh/ OFS/ Fresh & OFS)	Fresh Issue Size (by no. of shares or by amount in Rs.)	OFS Size (by no. of shares or by amount in Rs.)	Total Issue Size (by no. of shares or by amount in Rs.)	Issue Under 229 (1)/ (2)	Share Reservation		
					Market Maker	Retail Individuals	QIB & NII
Fresh Issue	16,08,000 Equity Shares aggregating to ₹ 402.00 Lakhs.	NA	16,08,000 Equity Shares aggregating to ₹ 402.00 Lakhs	229(1)	84,000 Equity Shares	7,62,000 Equity Shares	7,62,000 Equity Shares

These Equity Shares are proposed to be listed on SME Platform of BSE Limited ("BSE SME").

DETAILS OF OFS BY PROMOTERS / PROMOTER GROUP/ OTHER SELLING SHAREHOLDERS: N.A.

Price, Minimum Lot Size & Indicative Timelines

Price	₹ 25/- per Equity Share of Face Value of ₹10.00/- Each
Minimum Lot Size	6,000 Equity Shares
Issue Opens On	Tuesday, August 13, 2024
Issue Closes On*	Friday, August 16, 2024
Finalisation of Basis of Allotment	Monday, August 19, 2024
Initiation of Refunds	Tuesday, August 20, 2024
Credit of Equity Shares to Demat accounts of Allottees	Tuesday, August 20, 2024
Commencement of trading of Equity Shares	Wednesday, August 21, 2024

* UPI mandate end time and date shall be at 5:00 p.m. on the Issue Closing Date

For details of "Basis of Issue Price", please refer to page 77 of the Prospectus.

Details of Weighted Average Cost of Acquisition (WACA) of all shares transacted over the trailing eighteen months from the date of Prospectus:

Period	Weighted Average Cost of Acquisition (in ₹)	Issue Price is 'X' times the WACA	Range of acquisition price Lowest Price-Highest Price (in ₹)
Trailing Eighteen Months from the date of Prospectus	19.28	1.30 times*	10-45

*As certified by the Statutory Auditor, M/s K K Haryani & Co, Chartered Accountants, vide their certificate dated August 8, 2024.

WACA - Weighted average cost of acquisition

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

RISKS IN RELATION TO THE FIRST ISSUE

This being the first Public Issue of our Company, there has been no formal market for the securities of our Company. The face value of the shares is ₹ 10/- per Equity Shares and the Issue price is ₹ 25.00/- per Equity Share and the Issue Price is 2.50 times of the face value. The Issue Price (as determined by our Company in consultation with the Lead Manager) as stated in the chapter titled on “*Basis for Issue Price*” beginning on page 77 of the Prospectus should not be taken to be indicative of the market price of the Equity Shares after such Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares of our Company or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the section titled “*Risk Factors*” beginning on page 22 of the Prospectus and on page 8 of this Abridged Prospectus.

PROCEDURE

You may obtain a physical copy of the Application Form and the Prospectus from the stock exchange, Lead Manager, Registrar to the Issue, share transfer agents, depository participant’s, stock brokers, underwriters, bankers to the issue, investors’ associations or Self Certified Syndicate Banks.

If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the Prospectus and/or the General Information Document (GID) from the Lead Manager or download it from the websites of the Stock Exchange i.e. www.bseindia.com; and the Lead Manager www.fedsec.in.

PRICE INFORMATION OF LEAD MANAGER

DISCLOSURE OF PRICE INFORMATION OF PAST ISSUES HANDLED BY FEDEX SECURITIES PRIVATE LIMITED

Sr. No.	Issue Name	Issue Size (Cr)	Issue Price (₹)	Listing date	Opening price on listing date	+/- % change in closing price, [+/- % change in closing benchmark]- 30 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180 th calendar days from listing
MAINBOARD IPOs								
1.	Mukka Proteins Limited	224.00	28.00	March 07, 2024	40.00	35.54% 0.09%	11.07% (2.71) %	Not Applicable
SME IPOs								
1.	KK Shah Hospital	8.78	45.00	November 6, 2023	56.10	84.00% 6.68%	59.89% 10.43%	22.22% 13.73%
2.	IBL Finance Limited	33.40	51	January 16, 2024	56.00	22.35% (0.87%)	1.67% 1.09%	3.14% 11.59%
3.	Docmode Health Technologies Limited	6.71	79	February 02, 2024	190.25	162.03% 2.52%	230.82% 3.64%	26.58% 13.74%
4.	Baweja Studios Limited	97.20	180	February 06, 2024	183.00	23.94% 2.48%	(44.81%) 2.25%	(47.39%) 9.70%
5.	Polysil Irrigation Systems Limited	17.43	54.00	February 16, 2024	56.00	(35.63%) 0.07%	(32.31%) 0.73%	Not Applicable
6.	Deem Roll-Tech Limited	29.26	129.00	February 27, 2024	200.00	(29.15%) (0.34%)	(15.31%) 3.31%	Not Applicable
7.	Gconnect Logitech and Supply Chain Ltd	5.60	40	April 03, 2024	42.00	(11.30%) 0.99%	83.75% 7.58%	Not Applicable
8.	Vrudhhi Engineering Works Ltd	4.76	70	April 03, 2024	71.00	99.71% 0.99%	344.14% 7.58%	Not Applicable
9.	Finelistings Technologies Limited	13.53	123	May 14, 2024	127	(52.89) % 4.79%	Not Applicable	Not Applicable
10.	Magenta Lifecare Limited	7.00	35	June 12, 2024	45	15.26% 4.30%	Not Applicable	Not Applicable

Sources: All share price data is from www.bseindia.com and www.nseindia.com

Note:

- Opening price information as disclosed on the website of the Designated Stock Exchange.
- Change in closing price over the issue/offer price as disclosed on Designated Stock Exchange.
- For change in closing price over the closing price as on the listing date, the CNX NIFTY or S&P BSE SENSEX is considered as the Benchmark Index as per the Designated Stock Exchange disclosed by the respective Issuer at the time of the issue, as applicable.
- In case 30th/90th/180th day is not a trading day, closing price on BSE/NSE of the next trading day has been considered.
- In case 30th/90th/180th days, scrips are not traded then last trading price has been considered.
- This disclosure is restricted to last 10 issues handled by the Lead Manager.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

Name of Lead Manager and contact details	FEDEX SECURITIES PRIVATE LIMITED B 7, 3rd Floor, Jay Chambers, Dayaldas Road, Vile, Parle - (East), Mumbai - 400 057, Maharashtra, India Tel No: +91 8104985249 Email Id: mb@fedsec.in Website: www.fedsec.in Investor Grievance Email: mb@fedsec.in Contact Person: Saipan Sanghvi SEBI Registration Number: INM000010163
Name of Syndicate Members	Not Applicable
Name of Market Maker and contact details	AFTERTRADE BROKING PRIVATE LIMITED (formerly known as RCSPL Share Broking Private Limited) 206, 2nd floor, Time Square, Beside Pariseema Complex, C G Road, Navrangpura, Ahmedabad - 380009. Tel No: +91 7801918080 Email Id: compliance@aftertrade.in Website: www.aftertrade.in Investor Grievance Id: compliance@aftertrade.in Contact person: Tanmay Trivedi Sebi Registration no. INZ000155638
Name of Registrar to the Issue and contact details	KFIN TECHNOLOGIES LIMITED Selenium, Tower-B, Plot 31& 32, Gachibowli Financial District, Serilingampally, Hyderabad – 500032, Telangana, India Telephone: +91-40-6716-2222 Email: blhl.ipo@kfintech.com Investor Grievance Email ID: einward.ris@kfintech.com Contact Person: M Murali Krishna Website: www.kfintech.com SEBI Registration Number: INR000000221
Name of Statutory Auditor and Peer Review Auditor	M/s. K K HARYANI & CO., D/205-206, 2nd Floor, R. K. Casta, Station Road, Bharuch, 392001 Tel: + 264 2329700 Email: office@kkh.co.in / kishor_haryani@rediffmail.com Contact Person: Kishor Haryani Firm Registration: 121950W Membership Number: 110780 Peer Review Registration Number: 015994
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture trustee, if any	Not Applicable
Self-Certified Syndicate Banks	The lists of SCSBs notified by SEBI to act as SCSB for the ASBA process is available on the website of SEBI on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 . For details of the Designated Branches of SCSBs collecting the Application Forms, please refer to the above-mentioned SEBI link. The list of banks that have been notified by SEBI to act as SCSBs for the UPI process provided on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 The list of Branches of the SCSBs named by the respective SCSBs to receive deposits of the application forms from the designated intermediaries will be available on the website of the SEBI (www.sebi.gov.in) and updated from time to time.
Non-Syndicate Registered Brokers	You can submit Application Forms in the Issue to Non-Syndicate Registered Brokers at the Non-Syndicate Broker Centres. For further details, see section titled “ Issue Procedure ” beginning at page no. 256 of the Prospectus.
Self-Certified Syndicate Banks eligible as Issuer Banks and mobile applications enabled for UPI Mechanism	In accordance with SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019 and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 and SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, UPI Bidders using the UPI Mechanism may only apply through the SCSBs and mobile applications using the UPI handles specified on the website of the SEBI. The list of SCSBs through which Bids can be submitted by UPI Bidders using the UPI Mechanism, including details such as the eligible mobile applications and UPI handle which can be used for such Bids, is available on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 , as may be updated from time to time or at such other website as may be prescribed by SEBI from time to time.
Details regarding website address(es)/ link(s) from which the Investor can obtain list of Registrar to Issue and Share Transfer Agents, Depository Participants and Stock Brokers who can accept application from investor (as applicable)	The list of the RTAs eligible to accept ASBA Forms from Bidders (other than RIBs) at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the websites of Stock Exchanges at http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx? and https://www.nseindia.com/products-services/initial-public-offerings-asba-procedures , respectively, as updated from time to time. The list of the CDPs eligible to accept ASBA Forms from Bidders (other than RIBs) at the Designated CDP Locations, including details such as name and contact details, is provided on the websites of BSE at http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx? and on the website of NSE at https://www.nseindia.com/products-services/initial-public-offerings-asba-procedures , as updated from time to time. For further details, see “ Issue Procedure ” on page 256 of the Prospectus.

PROMOTERS OF THE COMPANY

Sr. No.	Name	Individual/Corporate	Experience & Educational Qualification
1.	Dr. Jaykumar Narendra Vyas	Individual	Dr. Jaykumar Narendra Vyas, aged 38 years is Promoter and Managing Director of our Company. He has been associated with our Company since its incorporation as a Director and Promoter. He holds a Bachelor of Medicine and bachelor’s of Surgery degree from Gujarat Medical Council. He also holds diploma of post graduate vocational training (residency training) in cardiology from I.M. Sechenov First Moscow State Medical University. He has around 10 years of experience in the field of cardiology. He is currently responsible for the overall management of the Company.
2.	Dr. Shachi Jaykumar Vyas	Individual	Dr. Shachi Jaykumar Vyas, aged 38 years, is the Promoter and Whole-time Director of our Company. She has been associated with our Company since its incorporation as a Director. She holds a bachelor’s of medicine and bachelor’s of surgery degree from Gujarat Medical Council. She also holds diploma of post graduate vocational training (residency training) in radiology from I.M. Sechenov First Moscow State Medical University. She has around 10 years of experience in the field of radiology.
3.	Mrs. Dhyuti Krupesh Joshi	Individual	Mrs. Dhyuti Krupesh Joshi, aged 45 years, is the Promoter, Chairman and Non - Executive Director of our Company. She holds a bachelor’s of Ayurvedic Medicine and Surgery degree under the Gujarat Board of Ayurvedic and Unani Systems of Medicine. She has around 5 years of experience in the field of medical and healthcare.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

BUSINESS OVERVIEW AND STRATEGY

Company Overview:

We operate our boutique Hospitals under the brand “*Maple Hospital*” and provide dedicated round-the-clock services to patients with heart ailments consisting of non-invasive cardiology services such as, 2D Echocardiography, Electrocardiography, Tread Mill Test, Holter monitoring, Ambulatory Blood Pressure Measurement, Stress test, Dobutamine Stress Echocardiography Subsequently, in the year June/July 2023 we ventured into interventional cardiac services such as, coronary angiography and stenting, percutaneous coronary intervention (“PCI”) and primary PCI for acute myocardial infarction as a division. We also provide Ballon mitral-valvuloplasty, permanent pacemaker implantation, cardiac resynchronisation procedures, implantable cardioverter-defibrillator (“AICD”) implantation and procedures for congenital ailments such as coarctation of aorta, stenting and posterior descending artery closure. We also offer a complete range of diagnostic and therapeutic options such as endovascular revascularization, deep vein thrombosis treatment and peripheral angioplasty.

Product/Service Offering Revenue segmentation by product/service offering

The following table sets forth a breakdown of our revenue from operations by geography for the periods indicated:

(₹ in lakhs)

Particulars	Broach Lifecare Hospital Limited for the financial year ended March 31, 2024	Dr. Vyas’s Hospital (“Sole Proprietorship Concern”)			
		Three months period ended June 30, 2023	As at, or for the fiscal year ended, March 31,		
			2023	2022	2021
Domestic/City	260.58	62.39	181.57	339.17	366.35
Bharuch	156.65	34.26	113.96	233.73	241.05
Ankleshwar	103.93	28.13	67.61	105.44	125.30
Exports	N.A.	N.A.	N.A.	N.A.	N.A.
Total	260.58	62.39	181.57	339.17	366.35

Geographies Served: Ankleshwar and Bharuch

Key Performance Indicators:

STANDALONE

(₹ In Lakhs except percentages and ratios)

Particulars	Broach Lifecare Hospital Limited for the financial year ended March 31, 2024	Dr. Vyas’s Hospital (“Sole proprietorship Concern”)			
		Three months period ended June 30, 2023*	As at, or for the fiscal year ended, March 31,		
			2023	2022	2021
Revenue from operations	260.58	62.39	181.57	339.17	366.35
Growth in Revenue from Operations ⁽¹⁾ (%)	43.51	-	(46.47)	(7.42)	-
Total income	260.58	68.84	192.49	347.66	380.24
EBITDA ⁽²⁾	102.61	45.71	87.44	135.68	133.53
EBITDA Margin ⁽³⁾	39.38	73.27	48.16	40.00	36.45
PAT	69.76	20.70	13.85	45.91	76.52
PAT Margin ⁽⁴⁾	26.77	33.18	7.63	13.54	20.89
*ROE ⁽⁵⁾	12.76	8.51	6.40	20.39	39.95
Capital Employed ⁽⁶⁾	546.92	901.12	809.98	480.55	263.18
*ROCE ⁽⁷⁾	17.09	4.09	5.77	21.42	44.54
Debt ⁽⁸⁾	0.00	657.99	593.66	255.41	71.61
Net Debt ⁽⁹⁾	(7.34)	594.45	573.65	248.36	59.33
Debt-Equity Ratio ⁽¹⁰⁾	0.00	2.71	2.74	1.13	0.37
Net Debt-EBITDA Ratio ⁽¹¹⁾	(0.07)	13.00	6.56	1.83	0.44
Net Tangible Assets ⁽¹²⁾	546.92	243.14	216.33	225.14	191.57
Monetary Assets ⁽¹³⁾	7.34	63.54	20.01	7.06	12.28
% of Monetary Assets to Net Tangible Assets ⁽¹⁴⁾	1.34	26.13	9.25	3.14	6.41
Net Worth ⁽¹⁵⁾	546.92	243.13	216.32	225.14	191.57
Return on Net Worth ⁽¹⁶⁾	12.76	8.51	6.40	20.39	39.95
Pre-Tax Operating Profit ⁽¹⁷⁾	93.45	30.40	34.66	62.26	103.59
Net Asset Value per Equity Share ⁽¹⁸⁾	12.26	N.A.	N.A.	N.A.	N.A.

As certified by K K Haryana & Co. Chartered Accountants. by way of their certificate dated August 6, 2024

* Not Annualized

^Company was incorporated on April 25, 2023

Notes:

- Growth in Revenue from Operations (%) is calculated as Revenue from Operations of the relevant period minus Revenue from Operations of the preceding period, divided by Revenue from Operations of the preceding period.
- EBITDA is calculated as the sum of (i) profit before tax and prior period items for the period/year; (ii) depreciation and amortization expenses, and (iii) finance costs.
- EBITDA Margin is calculated as EBITDA divided by Revenue from Operations.
- PAT Margin is calculated as profit for the period/year divided by Revenue from Operations.
- ROE is calculated as profit for the period/year divided by total equity.
- Capital Employed is calculated as total equity, plus non-current borrowings, plus current borrowing.
- ROCE is calculated as earnings before interest and taxes divided by Capital Employed.
- Debt is calculated as the sum of current borrowings and non-current borrowings
- Net Debt is calculated as total liabilities less cash & cash equivalents and bank balances.
- Debt-Equity Ratio is calculated as Debt divided by total equity.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

11. *Net Debt-EBITDA Ratio is calculated as Net Debt divided by EBITDA.*
12. *Net Tangible Assets is calculated as the sum of all the assets of our Company excluding, right of use assets and other intangible assets as reduced by total liabilities of our Company.*
13. *Monetary Assets is calculated as cash and cash equivalents and bank balances and excluding bank deposits with remaining maturity of more than twelve months and fixed deposits held as margin money.*
14. *% of Monetary Assets to Net Tangible Assets is calculated as Monetary Assets divided by Net Tangible Assets, expressed as a percentage.*
15. *Net Worth is calculated as the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.*
16. *Return on Net Worth is calculated as profit for the period/year divided by Net Worth.*
17. *Pre-Tax Operating Profit is calculated as profit before tax and prior period items for the period/year, excluding other income, finance cost.*
18. *Net Asset Value per Equity Share is calculated as Net Worth divided by the number of equity shares for the period/year as adjusted for bonus issue. Weighted average number of equity shares is the number of equity shares outstanding at the beginning of the year/period adjusted by the number of equity shares issued during the year/period multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the year/period.*

CONSOLIDATED -NA

Client Profile or Industries Served: Revenue segmentation in terms of top 5/10 clients or Industries-NA

Intellectual Property:

Our Company has not obtained registration and/or made applications for the registration of the trademark with Trademark Registry, Government of India. For more details, please refer chapter titled “Risk factors” beginning on page 22 of the Prospectus.

Market Share: Not Ascertainable.

Manufacturing Units: The Company does not possess any Manufacturing Units.

Employee Strength: As on March 31, 2024, we have around 19 employees on our payroll, to look after the day-to-day business operations.

Board of Directors: The Board of Directors as on the Prospectus are as follows:

Name of Directors	Designation	Experience & Educational Qualification	Other Directorship
Mrs. Dhyuti Krupesh Joshi	Chairman & Non-Executive Director	Mrs. Dhyuti Krupesh Joshi, aged 45 years, is the Chairman and Non - Executive Director of our Company. She holds a bachelor’s of Ayurvedic Medicine and Surgery degree under the Gujarat Board of Ayurvedic and Unani Systems of Medicine. She has around 5 years of experience in the field of medical and healthcare.	Indian Companies Public Limited Company: Nil Private Limited Company 1. Sargam Multispeciality Hospital Private Limited 2. Nostros Beverages Private Limited Foreign Companies: Nil
Dr. Jaykumar Narendra Vyas	Managing Director	Dr. Jaykumar Narendra Vyas, aged 38 years is Managing Director of our Company. He has been associated with our Company since its incorporation as a Director and Promoter. He holds a Bachelor of Medicine and bachelor’s of Surgery degree from Gujarat Medical Council. He also holds diploma of post graduate vocational training (residency training) in cardiology from I.M. Sechenov First Moscow State Medical University. He has around 10 years of experience in the field of cardiology. He is currently responsible for the overall management of the Company.	Indian Companies Public Limited Company: Nil Private Limited Company 1. Sargam Multispeciality Hospital Private Limited 2. Nostros Beverages Private Limited Foreign Companies: Nil
Dr. Shachi Jaykumar Vyas	Whole – Time Director	Dr. Shachi Jaykumar Vyas, aged 38 years, is the Whole-time Director of our Company. She has been associated with our Company since its incorporation as a Director. She holds a bachelor’s of medicine and bachelor’s of surgery degree from Gujarat Medical Council. She also holds diploma of post graduate vocational training (residency training) in radiology from I.M. Sechenov First Moscow State Medical University. She has around 10 years of experience in the field of radiology.	Indian Companies Public Limited Company: Nil Private Limited Company Nostros Beverages Private Limited Foreign Companies: Nil
Mehul Narendrakumar Hingu	Non - Executive Independent Director	Mr. Mehul Narendrakumar Hingu, aged 40 years is a Non-Executive Independent Director of our Company. He has been associated with our Company since December 9, 2023. He holds a bachelor’s of Commerce degree from Hemchandracharya North Gujarat University. He has over 15 years of experience in the field of accounting.	Indian Companies Public Limited Company Teja Engineering Industries Limited Private Limited Company Nil Foreign Companies Nil
Shrikrishna Ramesh Chaudhari	Non - Executive Independent Director	Mr. Shrikrishna Ramesh Chaudhari, aged 37 years is one of the Non-Executive Independent Director of our Company. He has been associated with our Company since December 15, 2023. He holds a bachelor’s of Science (Medical Laboratory Technology) degree from Yashwantrao Chavan Maharashtra Open University Nashik (India). He has around 9 years of experience in the field operating laboratories.	Indian Companies: Nil Foreign Companies: Nil

For further details, please refer chapter titled “**Our Management**” on page no. 125 of the Prospectus.

OBJECTS OF THE ISSUE

NET PROCEEDS

The details of the proceeds from the Issue are set out in the following table:

Particulars	Amount (₹ in Lakhs)
Gross Proceeds from the Fresh Issue	402.00
Less: Issue Related Expenses	45.00
Net Proceeds	357.00

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

UTILIZATION OF NET PROCEEDS AND SCHEDULE OF IMPLEMENTATION AND DEPLOYMENT

The Net Proceeds are currently expected to be deployed in accordance with the details provided in the table below:

The fund requirements for each of the objects of the Issue are stated as follows.

Particulars	Estimated Amount (₹ In Lakhs)
Purchase of Machineries	262.45
Development of Medical Tourism Web Portal	75.00
General corporate purposes*	19.55
IPO Expenses	45.00
Total	402.00

*The amount utilized for general corporate purposes shall not exceed 25% of the Gross Proceeds.

MEANS OF FINANCE

Fund requirements for the Objects are proposed to be met from the Net Proceeds and our internal accruals. Accordingly, we confirm that there is no requirement to make firm arrangements of finance under Regulation 230(1) of the SEBI ICDR Regulations 2018 and Clause 9 of Part A of Schedule VI of the SEBI ICDR Regulations 2018 through verifiable means towards at least 75% of the stated means of finance, excluding the amounts to be raised through the Issue or through existing identifiable internal accruals.

In case of a shortfall in raising requisite capital from the Net Proceeds towards meeting the objects of the Issue, we may explore a range of options including utilizing our internal accruals and seeking additional debt from existing and future lenders. We believe that such alternate arrangements would be available to fund any such shortfalls. Subject to applicable law, if the actual utilization towards any of the Objects, including utilization towards issue-related expenses, is lower than the proposed deployment, such balance will be used for towards the objects setout herein above, including general corporate purposes to the extent that the total amount to be utilized towards general corporate purposes will not exceed 25% of the Gross Proceeds from the Issue in accordance with the SEBI (ICDR) Regulations.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past Public Issues, if any, of the Company in the preceding 10 years: Not Applicable.

Name of monitoring agency, if any: Not Applicable

Terms of Issuance of Convertible Security, if any: Not Applicable

SHAREHOLDING PATTERN:

Sr. No.	Particulars	Pre-Issue Number of Equity Shares	% Holding of Pre-issue
1.	Promoter & Promoter Group	38,70,490	86.74%
2.	Public	5,91,890	13.26%
	Total	44,62,380	100.00%

Number/amount of Equity Shares proposed to be sold by selling shareholders: NA

SUMMARY OF RESTATED STANDALONE FINANCIAL INFORMATION

Particulars	Broach Lifecare Hospital Limited (Company)	Dr. Vyas's Hospital (Sole proprietorship Concern)			
		For the Period ended		For the Financial Year ended	
		For the Financial Year ended March 31, 2024	June 30, 2023	March 31, 2023	March 31, 2022
Share Capital (₹ in Lakhs)	446.24	1.00	1.00	1.00	1.00
Networth (₹ in Lakhs)	546.92	243.13	216.33	225.14	191.57
Revenue from operations (₹ in Lakhs)	260.58	62.39	181.57	339.17	366.35
Profit after Tax (₹ in Lakhs)	69.76	20.70	13.85	45.91	76.52
Earnings per share (Basic & diluted) (₹)	1.92	N.A.	N.A.	N.A.	N.A.
Net Asset Value per Equity Share (Basic & diluted) (₹)	12.26	N.A.	N.A.	N.A.	N.A.
Total borrowings (₹ in Lakhs)	0.00	657.99	593.66	255.41	71.61

CONSOLIDATED: NA

INTERNAL RISK FACTORS

The below mentioned risks are top 8 risk factors as per the Prospectus.

- Our Company has been formed specifically for the purpose of acquisition of the business of Dr. Vyas's Hospital (proprietorship concern of our Promoter i.e., Dr. Jaykumar Narendra Vyas) thus we have limited operating history as a Company which may make it difficult for investors to evaluate our historical performance or future prospects.
- We are highly dependent on our doctors and other healthcare professionals, as well as other key personnel and the loss of, or inability to attract or retain, such persons could adversely affect our business and results of operations..
- We are significantly dependent on our Promoters, Dr. Jaykumar Narendra Vyas, Dr. Shachi Jaykumar Vyas, and any loss of their services could adversely affect our business and results of operations.
- Our operations are geographically located in Bharuch and Ankleshwar in Gujarat at present and any localized social unrest, natural calamities, etc. could have material adverse effect on business and financial operations.
- We are a boutique hospital, primarily provide services relating to interventional cardiac services. Any material impact on our earnings from these fields will impact our financial condition and results of operations significantly..
- We derive a significant portion of our revenues from our tie up arrangements with insurance companies, third party administrators and corporations. The loss of any one or more of our major customers would have a material effect on our business operations and profitability.
- Delay in receipt of payment from our patients / customers may affect our cash flows, which may, in turn affect our financial condition and results of operations..
- Our ability to provide affordable healthcare depends on the maintenance of a high volume of patients, occupancy rates, managing operating and effective capital management. Any increase in such costs could adversely affect our business, financial condition and results of operations.

For further details, please refer chapter titled "Risk Factors" on page no. 22 of the Prospectus.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total number of outstanding litigations against the Company, Directors, Promoters and amount involved

Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount Involved (₹. in Lakhs)
Company						
By the Company	NIL	NIL	NIL	NIL	NIL	NIL
Against the Company	NIL	NIL	NIL	NIL	NIL	NIL
Others	NIL	NIL	NIL	NIL	NIL	NIL
Directors						
By our directors	NIL	NIL	NIL	NIL	NIL	NIL
Against the Directors	NIL	NIL	NIL	NIL	NIL	NIL
Others	NIL	NIL	NIL	NIL	NIL	NIL
Promoters						
By Promoters*	NIL	NIL	NIL	NIL	NIL	NIL
Against Promoters	NIL	1	NIL	NIL	NIL	0.71
others	NIL	NIL	NIL	NIL	NIL	NIL
Subsidiaries#						
By Subsidiaries	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Against Subsidiaries	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

For further details, please refer to “*Outstanding Litigation and Material Developments*” on page 229 of the Prospectus.

B. Brief details of top 5 material outstanding litigations against the company and amount involved: NIL

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: NIL

D. Brief details of outstanding criminal proceedings against Promoters: NIL

ANY OTHER IMPORTANT INFORMATION AS PER LEAD MANAGER / ISSUER COMPANY: N.A.

DECLARATION BY THE COMPANY

We hereby declare that all relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be have been complied with and no statement made in the Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made or guidelines or regulation issued there under, as the case may be. We further certify that all statements in the Prospectus are true and correct.

LIST OF SELF CERTIFIED SYNDICATE BANKS (SCSBs) UNDER THE ASBA PROCESS

Sr. No.	Name of the Bank	Controlling Branch & Address	Contact Person	Telephone Number	Fax Number	Email
1.	Axis Bank Ltd.	Centralised Collections and Payment Hub (CCPH) 5th Floor, Gigaplex, Building No. 1, Plot No.I.T.5, MIDC, Airoli Knowledge Park, Airoli, Navi Mumbai – 400708	Mr. Sunil Fadtare Assitant Vice President	022-71315906, 9819803730	022- 71315994	Sunil.fadtare@axisbank.com
2.	AU Small Finance Bank Limited	CP3 235, Industrial Area, Apparel Park, Mahal Road, Jagatpura, Jaipur, Rajasthan 302022	Vikrant Singh Sirohi	Mobile : +91 7340012357	-	epcasba@aubank.in
3.	Bandhan Bank	Adventz Infinity@5, BN Block, Sector V, Salt Lake City, Kolkata	Sagar Ranjan Das Senior Manager	Mobile : 9022339164	-	asba.business@bandhanbank.com
4.	Bank of Baroda	Mumbai Main Office, 10/12 Mumbai Samachar Marg, Fort, Mumbai-23	Mr. Sonu A. Arekar	022-40468314, 40468307,	022-22835236	asba.fortap@bankofbaroda.com
5.	Bank of Maharashtra	Fort Branch, 1st Floor, Janmangal, 45/47, Mumbai Samachar Marg, Mumbai – 400023	SHRI V R Kshirsagar (DGM)	022-22694160 22652595 22663947	022-22681296	brmgr2@mahabank.co.in; bom2@mahabank.co.in
6.	BNP Paribas	BNP Paribas House, 1, North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400051	Mr. Ashish. Chaturvedi, Mr. Dipu SA, Ms Prathima Madiwala	(022) 61964570/61964594/61964592	(022) 61964595	Ashish.chaturvedi@asia.bnpparibas.com comdipu.sa@asia.bnpparibas.com ma.madiwala@asia.bnpparibas.com
7.	Barclays Bank PLC	Barclays Bank PLC 601/603 Ceejay House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai – 400018	Parul Parmar	+91- 22 6719 6400/ 6575	+91- 22 6719 6996	Parul.parmar@barclays.com
8.	Bank of India	Phiroze Jeejeebhoy Tower, (New Stock Exchange Bldg), P. J. Tower, Dalal Street, Fort, Mumbai – 400 023.	Shri Navin Kumar Pathak, Senior Manager	022-22723631/1677/ 9619810717	022-22721782	Stockexchange.Mumbai,south@bankofindia.co.in
9.	Credit Suisse	10th Floor, Ceejay House, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018.	Yogesh Bachwani	098216 13306	-	yogesh.bachwani@credit-suisse.com
10.	CITI Bank NA	Citigroup Center, Plot No C-61, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051	S Girish	022-26535504, 98199 12248	022-26535824	s.girish@citi.com, asba.ops@citi.com
11.	Central Bank of India	Ground floor, Central Bank of India, Central Bank Building, Fort, Mumbai 400001	Mr. Vineet Bansaj	022- 22623148, 22623149	022-22623150	asba4082@centralbank.co.in
12.	Canara Bank	Canara Bank, Capital Market Service Branch,407, 4th floor, Himalaya House79, Mata Ramabai Ambedkar, Marg, MUMBAI-400 001	Mr. Arvind Namdev Pawar	022-22661618/ 22692973/ 9769303555	022-22664140	cb2422@canarabank.com, mbdcomcity@canarabank.com, hoembd@canarabank.com
13.	City Union Bank Ltd.	48, Mahalakshmi St., T. Nagar, Chennai - 600 017.Tamil Nadu.	Sivaraman	044 - 24340010, 24343517, 24346060, 24348586, 9380286558, 9382642081	044 - 24348586	cub001@cityunionbank.com
14.	DBS Bank Ltd.	DBS Bank Ltd, Fort House, 221, Dr. D.N. Road, Fort, Mumbai, 400 001	Amol Natekar	+91 22 6613 1213	+91 22 6752 8470	amolnatekar@db.com
15.	Dhanlaxmi Bank Limited	Ground Floor, Janmabhoomi Bhavan, Plot 11 -12, Janmabhoomi Marg, Fort Mumbai, Maharashtra – 400 001	Ramesh Menon	9167832288, 022- 22871658	-	ramesh.menon@dhanbank.co.in
16.	Deutsche Bank	Sidrah, 110, Swami Vivekananda Road, Khar (West), Mumbai 400052	Ms. Hetal Dholakia	(91) (022) 6600 9428 (91) (022) 6600 9419	-	hetal.dholakia@db.com manoj-s.naik@db.com; nanette.daryani@db.com.
17.	Equitas Small Finance Bank	CPC, Phase II, 4th floor, Spencer Plaza, No 769, Anna Salai, Chennai - 600002	Chandrashekar Arumugam	(M) 8939886802	-	asbaoperations@equitasbank.com; asbarecon@equitasbank.com

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

Sr. No.	Name of the Bank	Controlling Branch & Address	Contact Person	Telephone Number	Fax Number	Email
18.	GP Parsik Sahakari Bank Limited	Shivram Patil Bhavan, Parsik Nagar, Kalwa, Thane	Mr.Mayur M.Tanksale	022-25456655	-	mmtanksale800@gpparsikbank.net / pjsbasba@gpparsikbank.net
19.	HSBC Ltd.	3rd Floor, PCM Dept. Umang, Plot CTS No. 1406-A/28, Mindspace, Malad (West) Mumbai 400 064 (address of IPO Operations office)	Mr Jagrut Joshi	(022) 67115485/ 9870403732	(022) 66536005	jagrutjoshi@hsbc.co.in
20.	HDFC Bank Ltd.	FIG – OPS Department HDFC Bank Ltd Lodha - I Think Techno Campus-3 Level Next to Kanjurmarg Railway Station Kanjurmarg (East) Mumbai - 400042	Vincent Dsouza / Siddharth Jadhav / Prasanna Uchil	022-30752929 / 2927 / 2928	-	vincent.dsouza@hdfcbank.com, siddharth.jadhav@hdfcbank.com, prasanna.uchil@hdfcbank.com
21.	IDFC First Bank	Building no 2, Mindspace TTC Industrial Area, Juinagar. Navi Mumbai - 400 706	Mr. V M Praveen	022-49850025/ 9819708055	-	ASBA.CB@idfcfirstbank.com
22.	ICICI Bank Ltd.	ICICI BANK LIMITED, Capital Market Division, 1st Floor, 122, Mistry Bhavan, Dinshaw Vachha Road, Backbay Reclamation, Churchgate, Mumbai	Roshan Tellis	022-22859874/803	022-22611138	roshan.tellis@icicibank.com
23.	IDBI Bank Ltd.	IDBI Bank Limited Central Processing Unit, Sarju House, 3rd Floor, Plot No 7, Street No. 15, Andheri MIDC, Andheri (E), Mumbai.Pin : 400093	Shri. Naveen Nischal HP / Shri Viral Barodia	022- 66700525 / 685	-	hp.naveennischal@idbi.co.in / barodia.viral@idbi.co.in
24.	Indian Bank	Nandanam Branch- 480 Anna Salai, Nandanam 600035	Mr. V Muthukumar, Mr. M Veerabahu	044 24330233	044 24347755	nandanam@indianbank.co.in
25.	IndusInd Bank	IndusInd Bank Ltd. Fort Branch Sonawalla Bldg, Mumbai Samachar Marg, Fort, Mumbai 400001	Yogesh Adke Dy. Vice President	022-66366589 / 91 / 929833670809	022-22644834	yogesh.adke@indusind.com
26.	Indian Overseas Bank	Mexamine Floor, Cathedral Branch, 762 Anna Salai, Chennai 600 002	Mr. V. Srinivasan	044 - 28513616	-	deposit@jobnet.co.in
27.	J P Morgan Chase Bank, N.A.	J.P. Morgan Tower, Off C.S.T. Road, Kalina Santacruz - East, Mumbai - 400 098	Maresh Aras	022-61573811	022-61573949	Maresh.aras@jpmorgan.com/India.operations@jpmorgan.com
28.	Karur Vysya Bank Ltd.	Demat Cell, Second Floor No 29, Rangan Street, T Nagar, Chennai - 600 017	Maruthi Kumar Yenamandra	044- 24340374	044-24340374	maruthikumar@kvbmail.com, kvbpd@kvbmail.com
29.	Karnataka Bank Ltd	The Karnataka Bank Ltd Mangalore-H O Complex Branch Mahaveera Circle Kankanady Mangalore – 575002	Ravindranath Baglodi [Sr. Manager]	Ph: 0824-2228139 /140 /141	Fax: 0824-2228138	Email: mlr.hocomplex@ktkbank.com
30.	Kotak Mahindra Bank Ltd.	Kotak Infinity, 6 th Floor, Building No. 21, Infinity Park, Off Western Express Highway, General AK Vaidya Marg, Malad(E)	Prashant Sawant	D-+91 22 6605 6959M+91 9967636316	+91 66056642	prashant.sawant@kotak.com
31.	Mehsana Urban Co-Op. Bank Ltd.	Head Office, Urban Bank Road, Highway, Mehsana – 384002	Branch Manager	+91-2762-251908	+91-2762-240762	asba@mucbank.com
32.	Nutan Nagrik Sahakari Bank Ltd.	Opp Samratheshwar Mahadev, Nr, Law Garden, Ellisbridge, Ahmedabad-380006	Miti Shah	9879506795	7926564715	smiti@1977@yahoo.com
33.	Punjab National Bank	Capital Market Services Branch, PNB House, Fort, Sir P.M.Road Mumbai	Sh. K Kumar Raja	Tel – 022- 22621122, 22621123,	022 – 22621124	pnbcapsmumbai@pnb.co.in
34.	Punjab & Sind Bank	Rajindera Place- 21 Rajindra Place Bank House New Delhi-110008	RPS Sandhu	011- 25825784/25711836 9911129088	-	d0606@psb.co.in
35.	RBL Bank Limited	Techniplex – I, 9 th Floor, Off Veer Savarkar Flyover, Goregaon (West), Mumbai – 400062.	Shashikant Sanil	022-40288193, 022-40288196, 022-40288197	022-40288195	asba_ops@rblbank.com
36.	Rajkot Nagarik Sahakari Bank Ltd.	Nagrik Bhavan No 1 Parabazar Dhebarbhai Road Rajkot	Shri Yogesh Raveshiya	9427495222	(0281) 2233916/17/18	khmesh@rnsbindia.com; asba@rnsbindia.com
37.	SVC Co-Operative Bank Ltd.	Unit No.601-602-603 Dosti Pinnacle Plot No. E-7, Road No.22, Wagle Estate, Thane 400604	Mr. Omkar Anil Sukhathankar	(O) 71991460 71991461 71991462 71991463 71991465	-	sukhathankar@svcbank.com
38.	State Bank of India	State Bank of India, Capital Market Branch(11777),Videocon Heritage Building(Killick House),Charanjit Rai Marg, Fort, Mumbai – 400 001.	Ms. Raviti	Telephone:022-22094932 Mo-bile:9870498689	022-22094921	nib.11777@sbi.co.in
39.	Standard Chartered Bank	Crescenzo, 3rd Floor, C/38-39, G-Block, Opposite MCA Club, Bandra-Kurla Complex, Bandra [East], Mumbai 400-051	Rohan Ganpule	022 - 61157250 / 022 - 61157234	022 -26757358	lpo.scb@sc.com
40.	South Indian Bank	ASBA Cell (NODAL OFFICE) 2nd Floor, Shanu Towers, North Kalamassery, Ernakulam, Kerala - 683 104	John K Mechery	9645817905	0484-2351923	asba@sib.co.in
41.	The Federal Bank Limited	ASBA CELL, Retail Business Dept., Federal Bank, Marine Drive, Ernakulam 682031	Dhanya Dominic	0484-2201847	4842385605	rbd@federalbank.co.in/dhanyad@federalbank.co.in/riyajacob@federalbank.co.in
42.	Tamilnad Mercantile Bank Ltd.	Tamilnad Mercantile Bank Ltd., Depository Participant Services Cellthird Floor, Plot No.4923, Ac/16,2nd Avenue, Anna Nagar (West),Chennai - 600 040, Tamilnadu, India	Mr. N. Rajasegaran	044-26192552	044-26204174	dps@tmbonline.com
43.	The Jammu & Kashmir Bank Ltd.	79 A, Mehta House, Bombay Samachar Marg, Fort, Mumbai - 400 023.	Ashfaq Ahmad	9987984105, 022-66595971	022-6634183	bombay@jkbmail.com
44.	The Kalapur Commercial Co-Operative Bank Ltd.	Kalapur Bank Bhavan, Nr. Income Tax Circle, Ashram Road, Ahmedabad-380 014	Jay V. Pathak Manager	079-27582028	079-27544666	jay@kalapurbank.com
45.	The Surat Peoples Co-op Bank Ltd	Central Office. Vasudhara Bhavan, Timaliyawad, Nampura, Surat – 395001	Mr. Iqbal Shaikh	0261-2464577	0261-2464577,592	iqbal.shaikh@spcbl.in
46.	The Saraswat Co-operative Bank Ltd.	Madhushree, Plot No. 85, District Business Centre, Sector – 17, Vashi, Navi Mumbai – 400703	Mr. Ajit Babaji Satam	022-27884161 27884162 27884163 27884164	022-27884153	ab_satam@saraswatbank.com
47.	TJSB Sahakari Bank Ltd	2nd Floor, Madhukar Bhavan, Road No.16, Wagle Estate	Department Head	022-25838525/530/520		tjsbasba@tjsb.co.in
48.	Union Bank of India	MUMBAI SAMACHAR MARG,66/80, Mumbai Samachar Marg, Post Bag No.253 & 518, Fort, Mumbai - 400023.	Mr. D B JAISWAR	022-22629408	022- 22676685	jaiswar@unionbankofindia.com
49.	UCO Bank	Mumbai Main (Retail) Br., UCO Bank Bldg., D. N. Road, Mumbai- 400 023	Manager	022 40180117 9022457840	022-2222870754	bo.dnroad@mtnl.net.in
50.	Yes Bank Ltd.	YES Bank Limited, Indiabulls Finance Centre, Tower -II , 8th Floor, Senapati Bapat Marg, Elphinstone Road, Mumbai – 400 013.	Alok Srivastava / Shankar Vichare / Avinash Pawar	022 3347 7374/ 7259/ 7251	022 24214504	dlbtiservices@yesbank.in
51.	The Ahmedabad Mercantile Co-Op. Bank Ltd.	Head office :- "Amco House", Nr. Stadium Circle, Navrangpura, Ahmedabad-09	Bimal P Chokshi	079-26426582-84-88	079-26564863	amcoasba@rediffmail.com
52.	Catholic Syrian Bank Ltd.	P B No. 1900, Ground Floor, Marshall Annex Building, Soorji Vallabhdas Marg, Ballard Estate, Mumbai, Maharashtra, Pin- 400001	Ram Mohan G S	022-64502165, 022-22664269, 022-22665865, 022-22650850	-	mumbai@csb.co.in

ASBA Applicants may approach any of the above banks for submitting their application in the issue. For the complete list of SCSBs and their Designated Branches please refer to the website of SEBI <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=34>. A list of SCSBs is also displayed on the website of BSE at www.bseindia.com